Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Bladder Cancer |
Free Subscription
1 Actas Urol Esp (Engl Ed) |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder
cancer. Considerations in Latin America.
Actas Urol Esp (Engl Ed). 2024 Apr 12:S2173-5786(24)00058.
PubMed
The Long Noncoding RNA Gall Bladder Cancer-Associated Suppressor of Pyruvate
Carboxylase Inhibits the Proliferation, Migration, and Invasion of Colorectal
Cancer Cells and Induces Their Apoptosis.
Biochem Genet. 2024 Apr 12. doi: 10.1007/s10528-024-10786.
PubMed
Abstract available
Correction: Comprehensive analysis of mitochondria-related genes indicates that
PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via
Wnt signaling pathway.
Biol Direct. 2024;19:27.
PubMed
Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder
cancer.
BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
PubMed
Abstract available
Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder
cancer: a systematic review and meta-analysis of comparative studies.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
PubMed
Abstract available
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment
before radical cystectomy in bladder cancer patients.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
PubMed
Abstract available
Comparison of urological outcomes and quality of life after pelvic exenteration:
partial vs radical cystectomy.
BJU Int. 2024;133 Suppl 4:53-63.
PubMed
Abstract available
Quality of transurethral resection of bladder tumour documentation: implications
for non-muscle-invasive bladder cancer risk stratification and management.
BJU Int. 2024;133 Suppl 4:7-10.
PubMed
Comparing fluorodeoxyglucose positron emission tomography with computed
tomography in staging for nodal and distant metastasis in urothelial/bladder
cancer.
BJUI Compass. 2024;5:473-479.
PubMed
Abstract available
Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
BMC Urol. 2024;24:88.
PubMed
Abstract available
Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence.
Bratisl Lek Listy. 2024;125:311-317.
PubMed
Abstract available
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma
after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother. 2024;73:106.
PubMed
Abstract available
Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer
via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments.
Cancers (Basel). 2024;16:1267.
PubMed
Abstract available
Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic
Reprogramming beyond the Warburg Effect.
Cancers (Basel). 2024;16:1418.
PubMed
Abstract available
Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1366.
PubMed
Abstract available
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by
Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
Cancers (Basel). 2024;16:1356.
PubMed
Abstract available
Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder
Cancer: Comparison of Perioperative Outcomes.
Cancers (Basel). 2024;16:1329.
PubMed
Abstract available
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light
Cystoscopy: Insights from a Multicenter Registry.
Cancers (Basel). 2024;16:1268.
PubMed
Abstract available
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma
identifies driver hotspot mutations and a novel mutational signature.
Cell Genom. 2024;4:100528.
PubMed
Abstract available
Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major
Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical
Cystectomy.
Clin Genitourin Cancer. 2024 Mar 21:102079. doi: 10.1016/j.clgc.2024.102079.
PubMed
Abstract available
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in
Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
Clin Genitourin Cancer. 2024;22:102085.
PubMed
Abstract available
Preclinical models for bladder cancer therapy research.
Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
PubMed
Abstract available
Plasma metadherin mRNA expression in bladder cancer.
Egypt J Immunol. 2024;31:28-43.
PubMed
Abstract available
Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder
Cancer by Abrogating Immunosuppression.
Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.
PubMed
Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus
Open Radical Surgery: All Is in the Eye of the Beholder.
Eur Urol. 2024;85:431-432.
PubMed
Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion
Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled
Trial.
Eur Urol. 2024;85:422-430.
PubMed
Abstract available
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder
Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524
and RTOG 0712.
Eur Urol Oncol. 2024 Apr 18:S2588-9311(24)00095.
PubMed
Abstract available
Evaluation of tumor response to immune checkpoint inhibitors by a 3D
immunotumoroid model.
Front Immunol. 2024;15:1356144.
PubMed
Abstract available
THE EFFECT OF A MULTIMODAL APPROACH ON THE RESULTS OF TREATMENT IN SURGERY:
INTEGRATION OF CHEMOTHERAPY, SURGERY, AND RADIOTHERAPY.
Georgian Med News. 2024;:41-46.
PubMed
Abstract available
Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial
Carcinoma.
Int J Mol Sci. 2024;25:3695.
PubMed
Abstract available
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients
Who Respond to Immunotherapies Including Bacillus Calmette-Guerin and Immune
Checkpoint Inhibitors.
Int J Mol Sci. 2024;25:3800.
PubMed
Abstract available
Letter to the Editor Re: Variant histology is associated with more non-urothelial
tract recurrence but less intravesical recurrence upper tract urothelial
carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:420.
PubMed
Editorial comment to Lower bleeding volume contributes to decreasing surgical
site infection in radical cystectomy: A propensity score-matched comparison of
open versus robot-assisted radical cystectomy.
Int J Urol. 2024;31:437.
PubMed
Editorial Comment on Variant histology is associated with more non-urothelial
tract recurrence but less intravesical recurrence for upper tract urothelial
carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:418-419.
PubMed
Variant histology is associated with more non-urothelial tract recurrence but
less intravesical recurrence upper tract urothelial carcinoma after radical
nephroureterectomy.
Int J Urol. 2024;31:421.
PubMed
Editorial comment to "The clinical impact of ureteroscopy for upper tract
urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:402-403.
PubMed
Editorial Comment on "The clinical impact of ureteroscopy for upper tract
urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:401-402.
PubMed
Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in
patients with advanced urothelial cancer: A multicenter observational study.
Int J Urol. 2024;31:348.
PubMed
Older versus younger patients in robot-assisted radical cystectomy with
intracorporeal ileal conduit comparing safety and clinical outcomes.
Int J Urol. 2024;31:370-378.
PubMed
Abstract available
Lower bleeding volume contributes to decreasing surgical site infection in
radical cystectomy: A propensity score-matched comparison of open versus
robot-assisted radical cystectomy.
Int J Urol. 2024;31:430-437.
PubMed
Abstract available
Prognostic factors for overall survival in clinical node-positive patients with
upper tract urothelial carcinoma.
Int J Urol. 2024;31:386-393.
PubMed
Abstract available
Variant histology is associated with more non-urothelial tract recurrence but
less intravesical recurrence for upper tract urothelial carcinoma after radical
nephroureterectomy.
Int J Urol. 2024;31:410-418.
PubMed
Abstract available
The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A
multicenter study.
Int J Urol. 2024;31:394-401.
PubMed
Abstract available
Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular
considerations in 5-aminolevulinic acid use for bladder tumors.
Int J Urol. 2024;31:452.
PubMed
circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and
stabilizing p53 mRNA.
iScience. 2024;27:109624.
PubMed
Abstract available
The role of histological subtype and chemotherapy on prognosis of ureteral
cancer.
J Cancer Res Clin Oncol. 2024;150:192.
PubMed
Abstract available
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid
Instillations in Bladder Cancer.
J Clin Med. 2024;13:2031.
PubMed
Abstract available
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth
Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A
Combined Analysis of Two Phase II Clinical Trials.
J Clin Oncol. 2024;42:1391-1402.
PubMed
Abstract available
J Clin Tuberc Other Mycobact Dis
Chest wall tumor following intravesical BCG instillation for non-muscle invasive
bladder cancer.
J Clin Tuberc Other Mycobact Dis. 2024;35:100438.
PubMed
Abstract available
Spatial comparison of molecular features associated with resistance to
pembrolizumab in BCG unresponsive bladder cancer.
J Immunother Cancer. 2024;12:e008571.
PubMed
Abstract available
Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer:
a novel molecular subtyping strategy and immunotherapeutic prediction model.
J Transl Med. 2024;22:365.
PubMed
Abstract available
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth
Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial
(EAY131) Subprotocol K2.
JCO Precis Oncol. 2024;8:e2300407.
PubMed
Abstract available
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications:
Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol. 2024;8:e2300406.
PubMed
Abstract available
A lightweight bladder tumor segmentation method based on attention mechanism.
Med Biol Eng Comput. 2024;62:1519-1534.
PubMed
Abstract available
Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-kappaB signaling pathway
leads to the formation of a loop between HIF-1alpha and MUC1-C promoting
chemoresistance in bladder cancer.
Mol Carcinog. 2024 Apr 18. doi: 10.1002/mc.23725.
PubMed
Abstract available
A CAF subpopulation promotes LVI in early-stage bladder cancer.
Nat Rev Urol. 2024 Apr 15. doi: 10.1038/s41585-024-00881.
PubMed
Predicting non-muscle invasive bladder cancer outcomes using artificial
intelligence: a systematic review using APPRAISE-AI.
NPJ Digit Med. 2024;7:98.
PubMed
Abstract available
Natural history and health care burden of non-curative treatment for
muscle-invasive bladder cancer.
Urol Oncol. 2024 Apr 18:S1078-1439(24)00365.
PubMed
Abstract available
Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients
with urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol. 2024;42:160.
PubMed
Abstract available
The association between frailty, hypogonadism, and postoperative outcomes among
men undergoing radical cystectomy.
Urol Oncol. 2024;42:161.
PubMed
Abstract available
Regional differences in upper tract urothelial carcinoma patients across the
United States.
Urol Oncol. 2024;42:162.
PubMed
Abstract available
Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy:
A systematic review and meta-analysis.
Urol Oncol. 2024;42:121-132.
PubMed
Abstract available
Incidence of Ureteroenteric Anastomotic Strictures After Robotic vs Open
Cystectomy in Adults.
Urology. 2024;185:100-108.
PubMed
Abstract available
Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN
estimates.
World J Urol. 2024;42:237.
PubMed
Abstract available
[Identification of lncrnas associated with aniline toxicity in male bladder
cancer and construction of tumor risk prediction models].
Zhonghua Nan Ke Xue. 2023;29:790-798.
PubMed
Abstract available
Thank you for your interest in scientific medicine.